The landscape of genetic treatments for Leber Hereditary Optic Neuropathy (LHON) continues to expand as Neurophth Therapeutics advances its phase 1/2/3 GOLD clinical trial. The trial is evaluating NR082 (esonadogene mvoparvovec), an investigational gene therapy designed to treat LHON patients carrying the mtND4 mutation.
NR082 utilizes a recombinant adeno-associated viral vector (rAAV2) to deliver a codon-optimized version of the NADH-dehydrogenase subunit 4 (ND4) gene directly to the damaged retinal ganglion cells. By providing a functional copy of the gene, the therapy aims to restore mitochondrial function, improve cellular energy production, and ultimately rescue visual function.
The GOLD trial is a comprehensive, multi-part study taking place in China. Following a successful dose-finding phase (Part 1), the trial has progressed to its phase 3 portion (Part 2), which involves a randomized, double-blind, sham-injection controlled study. The primary endpoint for this pivotal stage is the proportion of study eyes achieving a 0.3 LogMAR or greater increase in best-corrected visual acuity (BCVA) at 52 weeks post-treatment.
In addition to the GOLD trial in China, Neurophth has also completed patient enrollment for a phase 1/2 clinical trial of NR082 in the United States, marking a significant step in the global development of the therapy. NR082 has already received orphan drug designation from both the U.S. FDA and the European Medicines Agency (EMA), underscoring the urgent unmet medical need in the LHON community.
As the GOLD trial progresses toward its estimated completion in 2028, the ophthalmic community eagerly anticipates the results. If successful, NR082 could provide a vital new therapeutic option for patients facing the rapid and debilitating vision loss characteristic of LHON.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.